Stockreport

Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases

Alexion Pharmaceuticals, Inc  (ALXN) 
Last alexion pharmaceuticals, inc earnings: 1/30 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.alexion.com/investor-relations
PDF - Elamipretide in Phase 3 development for primary mitochondrial myopathy -- If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipr [Read more]